Chromium Supplementation for Menstrual Cycle-Related Mood Symptoms

REFERENCES

• American Psychiatric Association. Diagnostic and statistical manual of mental disorders. fourth edition text revision. Washington, DC: American Psychiatric Press, 2000.
   Google Scholar
• Anderson RA, Polansky MM, Bryden NA, Bhathena SJ, Canary JJ. Effects of supplemental chromium on patients with symptoms of reactive hypoglycemia. Metabolism. 1987;36(4):351–355.
   PubMedGoogle Scholar
• Attenburrow MJ, Odontiadis J, Murray BJ, Cowen PJ, Franklin M. Chromium treatment decreases the sensitivity of 5-HT2A receptors. Psychopharmacology (Berl). 2002;159(4):432–436.
   PubMed Web of Science ®Google Scholar
• Cohen LS, Soares CN, Yonkers KA, Bellew KM, Bridges IM, Steiner M. Paroxetine controlled release for premenstrual dysphoric disorder: a double-blind, placebo-controlled trial. Psychosom Med. 2004;66(5):707–713.
   PubMedGoogle Scholar
• Davidson JRT, Abraham K, Connor KM, McLeod MN. Effectiveness of chromium in atypical depression: a placebo-controlled trial. Biol Psychiatry. 2003;53(3):261–264.
   PubMed Web of Science ®Google Scholar
• Davis CM, Vincent JB. Chromium oligopeptide activates insulin receptor tyrosine kinase activity. Biochemistry. 1997;36(15):4382–4385.
   PubMedGoogle Scholar
• Derogatis L. SCL-90-R administration, scoring, and procedures manual. Baltimore, MD: Clinical Psychometric Research, 1983.
   Google Scholar
• Dimmock PW, Wyatt KM, Jones PW, O'Brien PM. Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome: a systematic review. Lancet. 2000;356(9236):1131–1136.
   PubMed Web of Science ®Google Scholar
• Docherty JP, Sack DA, Roffman M, Finch M, Komorowski JR. A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving. J Psychiatr Pract. 2005;11:302–314.
   PubMedGoogle Scholar
• Endicott J, Harrison W. Daily rating of severity of problems form. New York: Department of Research Assessment and Training, New York State Psychiatric Institute, 1990.
   Google Scholar
• Eriksson E, Ekman A, Sinclair S, Sörvik K, Ysander C, Mattson UB, Nissbrandt H. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol. 2008;28(2):195–202.
   PubMed Web of Science ®Google Scholar
• Fernstrom JD, Wurtman RJ. Brain serotonin content: physiological dependence on plasma tryptophan levels. Science. 1971;173(992):149–152.
   PubMedGoogle Scholar
• Franklin M, Odontiadis J. Effects of treatment with chromium picolinate on peripheral amino acid availability and brain monoamine function in the rat. Pharmacopsychiatry. 2003;36(5):176–180.
   PubMedGoogle Scholar
• Freeman EW, Rickels K, Sammel MD, Lin H, Sondheimer SJ. Time to relapse after short- or long-term treatment of severe premenstrual syndrome with sertraline. Arch Gen Psychiatry. 2009;66(5):537–544.
   PubMedGoogle Scholar
• Freeman EW, Sondheimer SJ. Premenstrual dysphoric disorder: recognition and treatment. Prim Care Companion J Clin Psychiatry. 2003;5(1):30–39.
   PubMedGoogle Scholar
• Geiselman PJ. Sugar-induced hyperphagia: is hyperinsulinemia, hypoglycemia, or any other factor a “necessary” condition? Appetite. 1988;11(Suppl 1):26–34.
   PubMedGoogle Scholar
• Ghosh D, Bhattacharya B, Mukherjee B, Manna B, Sinha M, Chowdhury J, Chowdhury S. Role of chromium supplementation in Indians with type 2 diabetes mellitus. J Nutr Biochem. 2002;13(11):690–697.
   PubMed Web of Science ®Google Scholar
• Guy E. ECDEU assessment manual for psychopharmacology—revised, pp. 218–222. Rockville, MD: U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976.
   Google Scholar
• Halbreich U, Borenstein J, Pearlstein T, Kahn LS. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology. 2003;28(Suppl 3):1–23.
   Google Scholar
• Halbreich U. Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectr. 2008;13(7):566–572.
   PubMedGoogle Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56–62.
   PubMed Web of Science ®Google Scholar
• Institute of Medicine (IOM). Chromium picolinate: prototype monograph. In Dietary supplements: A framework for evaluating safety, pp. B1–B80. Washington, DC: Institute of Medicine, 2004.
   Google Scholar
• Khanam R, Pillai KK. Effect of chromium picolinate on modified forced swimming test in diabetic rats: involvement of serotonergic pathways and potassium channels. Basic Clin Pharmacol Toxicol. 2006;98(2):155–159.
   PubMedGoogle Scholar
• Lydic ML, McNurland M, Bembo S, Mitchell L, Komaroff E, Gelato M. Chromium picolinate improves insulin sensitivity in obese subjects with polycystic ovary syndrome. Fertil Steril. 2006;86:243–246.
   PubMedGoogle Scholar
• Martin J, Wang ZQ, Zhang XH, Wachtel D, Volaufova J, Matthews DE, Cefalu WT. Chromium picolinate supplementation attenuates body weight gain and increases insulin sensitivity in subjects with Type 2 diabetes. Diabetes Care. 2006;29:1826–1832.
   PubMed Web of Science ®Google Scholar
• McCarty MF. Enhancing central and peripheral insulin activity as a strategy for the treatment of endogenous depression—an adjuvant role for chromium picolinate? Med Hypotheses. 1994;43(4):247–252.
   PubMedGoogle Scholar
• McLeod MN, Gaynes BN, Golden RN. Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients. J Clin Psychiatry. 1999;60(4):237–240.
   PubMedGoogle Scholar
• McLeod MN, Golden RN. Chromium treatment of depression. Int J Neuropsychopharmacol. 2000;3(4):311–314.
   PubMedGoogle Scholar
• Piotrowska A, Mlyniec K, Siwek A, Dybala M, Opoka W, Poleszak E, Nowak G. Antidepressant-like effect of chromium chloride in the mouse forced swim test: involvement of glutamatergic and serotonergic receptors. Pharmacol Rep. 2008;60(6):991–995.
   PubMed Web of Science ®Google Scholar